Edition:
India

Vertex Pharmaceuticals Inc (VRTX.OQ)

VRTX.OQ on NASDAQ Stock Exchange Global Select Market

157.97USD
19 Jan 2018
Change (% chg)

$0.78 (+0.50%)
Prev Close
$157.19
Open
$157.30
Day's High
$159.48
Day's Low
$156.32
Volume
676,784
Avg. Vol
531,908
52-wk High
$167.70
52-wk Low
$80.08

Select another date:

Wed, Jan 10 2018

BRIEF-Vertex Receives EU Approval For Orkambi

* VERTEX RECEIVES EU APPROVAL FOR ORKAMBI® (LUMACAFTOR/IVACAFTOR) IN CHILDREN WITH CYSTIC FIBROSIS AGES 6-11 WITH TWO COPIES OF THE F508DEL MUTATION Source text for Eikon: Further company coverage:

BRIEF-Vertex, CRISPR Therapeutics To Co-Develop CTX001 As CRISPR/Cas9 Gene Edited Treatment

* VERTEX AND CRISPR THERAPEUTICS TO CO-DEVELOP AND CO-COMMERCIALIZE CTX001 AS CRISPR/CAS9 GENE EDITED TREATMENT FOR SICKLE CELL DISEASE AND Β-THALASSEMIA

BRIEF-Vertex Announces Positive Results From Open-Label Phase 3 Study Of KALYDECO(ivacaftor)

* VERTEX ANNOUNCES POSITIVE RESULTS FROM OPEN-LABEL PHASE 3 STUDY OF KALYDECO® (IVACAFTOR) IN CHILDREN WITH CYSTIC FIBROSIS AGES 1 TO 2 YEARS

BRIEF-Vertex receives CHMP positive opinion for Orkambi for the treatment of children with cystic fibrosis ages 6-11

* Vertex receives CHMP positive opinion for Orkambi® (lumacaftor/ivacaftor) for the treatment of children with cystic fibrosis ages 6-11 with two copies of the f508del mutation in the European Union Source text for Eikon: Further company coverage:

Vertex posts wider net loss, raises cystic fibrosis sales outlook

Oct 25 Vertex Pharmaceuticals Inc reported a wider third-quarter net loss on Wednesday, on higher costs and onetime items, and raised its outlook for full-year sales of its key cystic fibrosis drugs.

BRIEF-Vertex says FDA sets action date of Feb 28, 2018 for its Tezacaftor/Ivacaftor Combination Treatment

* Vertex announces acceptance of its applications for review of the tezacaftor/ivacaftor combination treatment in people with cystic fibrosis by the FDA and EMA

BRIEF-FDA approves Kalydeco(Ivacaftor) for more than 600 people ages 2 and older with Cystic Fibrosis who have certain residual function mutations

* FDA approves Kalydeco (Ivacaftor) for more than 600 people ages 2 and older with Cystic Fibrosis who have certain residual function mutations

BRIEF-Vertex interested in early stage assets consistent with CF focus

* Vertex says interested in acquiring early stage assets in disease areas consistent with cystic fibrosis

UPDATE 1-Vertex Pharma's quarterly profit beats estimates

July 26 Vertex Pharmaceuticals Inc reported a better-than-expected profit for the third straight quarter, helped by improved sales of its cystic fibrosis (CF) drugs.

Vertex Pharma reports quarterly profit

July 26 Vertex Pharmaceuticals Inc reported a quarterly profit, compared with a year-ago loss, helped by higher sales of its cystic fibrosis (CF) drugs.

Select another date: